Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin (PLY) from Streptococcus pneumoniae

Vaccine

Volumn 28, Issue 18, 2010, Pages 3231-3237

  Douce, Gill ^a   Ross, Kirsty ^a   Cowan, Graeme ^a   Ma, Jiangtao ^a   Mitchell, Tim J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Mucosal adjuvant; Non toxic; Pneumolysin

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PNEUMOLYSIN; STREPTOCOCCUS ANTIGEN; STREPTOCOCCUS ANTIGEN PNEUMOLYSIN FUSION PROTEIN; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; GENE FUSION; IMMUNOGENICITY; INFECTION RESISTANCE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION;

ADHESINS, BACTERIAL; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; BACTERIAL PROTEINS; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPROTEINS; MICE; MICE, INBRED BALB C; PROTEINS; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; STREPTOLYSINS; VACCINES; VACCINES, SYNTHETIC;

EID: 77949657612     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.014     Document Type: Article

References (28)

1. Poulain-Godefroy O., Menozzi F.D., Alonso S., Vendeville C., Capron A., Locht C., et al. Adjuvant activity of free Bordetella pertussis filamentous haemagglutinin delivered by mucosal routes. Scand J Immunol 58 (2003) 203-510
2. Marinaro M., Fasano A., and De Magistris M.T. Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses. Infect Immun 71 (2003) 1897-1902
3. Orr B., Douce G., Baillie S., Parton R., and Coote J. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. Vaccine 25 (2006) 64-71
4. Holmgren J., Adamsson J., Anjuère F., Clemens C., Czerskinsky C., Eriksson K., et al. Mucosal adjuvants and anti-infection and anti immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 15 (2005) 181-188
5. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., et al. Mucosal vaccines: nontoxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19 (2001) 2534-2541
6. Rappuoli R., Pizza M., Douce G., and Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 20 (1999) 493-500
7. Lapa J.A., Sincock S.A., Ananthakrishnan M., Porter C.K., Cassels F.J., Brinkley C., et al. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. Clin Vaccine Immunol 15 (2008) 1222-1228
8. Gockel C.M., and Russell M.W. Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein. Immunology 116 (2005) 477-486
9. Johnson M.K., Geoffroy C., and Alouf J.E. Binding of cholesterol by sulfhydryl-activated cytolysins. Infect Immun 27 (1980) 97-101
10. Kirkham L.A., Kerr A.R., Douce G.R., Paterson G.K., Dilts D.A., Lui F., et al. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun 74 (2006) 586-593
11. Alexander J.E., Lock R.A., Peeters C.A.M., Poolman J.T., Andrew P.W., Mitchell T.J., et al. Immunisation of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 62 (1994) 5683-5688
12. Paton J.C., Lock R.A., Lee C.J., Li J.P., Berry A.M., Mitchell T.J., et al. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniase type 19F polysaccharide. Infect Immun 59 (1991) 2297-2304
13. Fickl H., Cockeran R., Steel H., Feldman C., Cowan G., Mitchell T., et al. Pneumolysin-mediated activation of NFkappaB in human neutrophils is antagonized by docosahexaenoic acid. Clin Exp Immunol 140 (2005) 274-281
14. Srivastava A., Henneke P., Visintin A., Morse S.C., Martin V., Watkins C., et al. The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect Immun 73 (2005) 6479-6487
15. Malley R., Henneke P., Morse S.C., Cieslewicz M.J., Lipstitch M., Thompson C.M., et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 100 (2003) 1966-1971
16. Crook J., Tharpe J.A., Johnson S.E., Williams D.B., Stinson A.R., Facklam E.W., et al. Immunoreactivity of monoclonal antibodies against the 37 kilodalton common cell wall protein (PsaA) of Streptococcus pneumoniae. Clin Diagn Lab Immunol 5 (1998) 205-210
17. Pimenta F.C., Miyanji E.N., Areas A.P.M., Oliverira A.L.S., De Andrade A.L.S.S., Ho P.L., et al. Intranasal immunisation with the cholera toxin B subunit-pneumococcal surface antigen. A fusion protein induces protection against colonisation with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice. Infect Immun 74 (2006) 4939-4944
18. Freitag N.E., and Jacobs K.E. Examination of Listeria monocytogenes intracellular gene expression by using the green fluorescent protein of Aequorea victoria. Infect Immun 67 4 (1999) 1844-1852
19. Beurg M., Hafidi A., Skinner L., Cowan G., Hondarrague Y., Mitchell T.J., et al. The mechanism of pneumolysin-induced cochlear hair cell death in the rat. J Physiol 568 (2005) 211-227
20. Heim R., Prashe D., and Tsien R. Wavelength mutations and posttranslational autooxidation of green fluorescent protein. Proc Natl Acad Sci USA 91 (1994) 12501-12504
21. Walker J.A., Allen R.L., Falmagne P., Johnson M.K., and Boulnois G.J. Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae. Infect Immun 55 (1987) 1184-1189
22. Cropley I., Douce G., Roberts M., Chatfield S., Pizza M., Marsili I., et al. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment. Vaccine 17 (1995) 1643-1648
23. Douce G., Fontana M., Pizza M., Rappuoli R., and Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 65 (1997) 2821-2828
24. Gunn G.R., Zubair A., Peters C., Zhen-Kun P., Wu T.C., and Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumours immortalised by HPV-16. J Immunol 167 (2001) 6471-6479
25. Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68 (2000) 796-800
26. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 32 (2006) 139-153
27. Douce G., Giuliani M.M., Giannelli V., Pizza M., Rappuoli R., and Dougan G. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16 (1998) 1065-1073
28. Areas A.P.M., Oliveira M.L.S., Miyanji E.N., Leite L.C.C., Aires K.A., Dias W.O., et al. Expression and characterisation of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CT-B-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun 321 (2004) 192-196